Drug Profile
Osteocalcin-thymidine kinase gene therapy
Alternative Names: Ad-OC-hsv-TK; Ad-OC-TKLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone cancer; Prostate cancer